JAMA Psychiatry
March 25, 2026
Wiesław Jerzy Cubała, Malek Bajbouj, Michael Bauer et al.
3 citations
A single day of treatment with an inhaled synthetic formulation of mebufotenin (GH001) significantly reduced depression symptoms in adults with treatment-resistant depression compared to placebo. In a randomized, double-blind trial of 81 patients, those receiving up to three escalating doses of GH001 showed an average 15.5-point greater improvement on the Montgomery-Åsberg Depression Rating Scale by day 8 than those on placebo. Remission rates were 57.5% for GH001 and 0% for placebo. No severe or serious adverse events occurred. The findings suggest GH001 may be a rapid-acting, well-tolerated treatment option for treatment-resistant depression.
Schizophrenia bulletin
November 16, 2024
Inge Hahne, Marco Zierhut, Niklas Bergmann et al.
3 citations
A yoga-based group intervention (YoGI) added to treatment-as-usual is feasible and acceptable for inpatients with schizophrenia spectrum disorders (SSD). In a randomized controlled trial with 50 inpatients, YoGI plus treatment-as-usual showed 95% protocol adherence, 91-94% retention, and a 6% dropout rate. Compared to treatment-as-usual alone, the yoga group had significant improvements in positive symptoms, depression, cognitive fusion, and a mindfulness subscale. Medium-to-large improvements were also seen in body mindfulness, negative and general symptoms, anxiety, stress, quality of life, and attention. No severe adverse events occurred. The findings suggest YoGI may provide benefits beyond standard care, but further robust trials are needed.
medRxiv
July 4, 2026
Marco Zierhut, Max Alt, Inge Maria Hahne et al.
Combining intranasal oxytocin with mindfulness-based group therapy may improve negative symptoms in schizophrenia spectrum disorders. In a pilot study, 47 participants received either oxytocin or placebo before four therapy sessions. Only the oxytocin group showed significant reductions in negative symptoms from baseline to post-intervention and at a 4-week follow-up, with small between-group effects favoring oxytocin at follow-up. No serious adverse events occurred. The findings support further large-scale trials.